1UB.F · Cognetivity Neurosciences Ltd

-

Please sign in to comment on 1UB.F

1 Comment

Admin

3 years, 7 months ago

Cognetivity Neurosciences Ltd is currently in a long term uptrend where the price is trading 76.9% above its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Cognetivity Neurosciences Ltd's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 87.3% to $-96K since the same quarter in the previous year.

Finally, its free cash flow grew by 76.7% to $-31K since the same quarter in the previous year.

Based on the above factors, Cognetivity Neurosciences Ltd gets an overall score of 4/5.

CurrencyCode	EUR
Exchange	F
Sector	Healthcare
ISIN	CA19243C1005
Industry	Health Information Services

PE Ratio	None
Market Cap	17M
Beta	0.07
Dividend Yield	0.0%
Target Price	None

ABOUT

Cognetivity Neurosciences Ltd

Cognetivity Neurosciences Ltd. operates as a technology company. It develops an integrated cognitive assessment, a cognitive testing platform for use in medical, commercial, and consumer environments that allows early diagnosis of dementia, as well as other neurological conditions. The company was formerly known as Utor Capital Corp. and changed its name to Cognetivity Neurosciences Ltd. in December 2017. Cognetivity Neurosciences Ltd. was incorporated in 2015 and is headquartered in Vancouver, Canada.

1UB.F · Cognetivity Neurosciences Ltd

-

Cognetivity Neurosciences Ltd

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Cognetivity Neurosciences Ltd using a moving average strategy